Trial Profile
4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs Bepotastine (Primary)
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Hanlim Pharmaceutical
- 01 Mar 2021 Primary endpoint (Changes in total rTNSS(Reflective TNSS) score) has been met , according to Results published in the Laryngoscope
- 01 Mar 2021 Results published in the Laryngoscope
- 06 Sep 2018 New trial record